Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Living Cell Technologies Granted European Patent

Living Cell Technologies Limited

 
Living Cell Technologies Granted European Patent for Neurological Disease Product NTCELL

NTCELL targets neurological diseases such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis and Huntington’s disease and Stroke
Patent based on technology of implanting encapsulated porcine choroid plexus cells
Journal of Neural Engineering publishes LCT’s latest data on therapeutic benefit of choroid plexus cell implants

20 January 2010: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted a European patent for the use of its product NTCELL in the treatment of degenerative neurological conditions such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis (MS), Huntington’s disease and Stroke.

LCT’s European patent is based on the technology of preparing NTCELL, which are encapsulated porcine cells of the choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and to enhance the natural repair mechanisms in the brain. NTCELL has the potential to restore neural cells and tissue.

The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs.

Dr Paul Tan, Chief Executive Officer LCT said: “At a time when we are seeing regulatory approvals in Europe and the US for clinical trials with cell-based therapeutics in neurologic disorders, we can expect NTCELL to add significant value to LCT. The granting of this key patent for NTCELL coincides with the publication of LCT’s most recent data on cell therapy for neurological diseases in a leading peer review journal.”

The December 2009 issue of the Journal of Neural Engineering published LCT’s paper titled “Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma”, which shows that long-lasting therapeutic implants of NTCELL may be used to treat brain disease. The new experimental data indicates that the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors. The implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. This publication adds to LCT’s previously published and presented data on the beneficial effects of NTCELL implants in animal models of Parkinson’s disease, Huntington’s disease, stroke and hearing loss caused by degeneration of the auditory nerve.

 

-Ends-

 

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

By May 2018: Wider, Earlier Microbead Ban

The sale and manufacture of wash-off products containing plastic microbeads will be banned in New Zealand earlier than previously expected, Associate Environment Minister Scott Simpson announced today. More>>

ALSO:

Snail-ier Mail: NZ Post To Ditch FastPost

New Zealand Post customers will see a change to how they can send priority mail from 1 January 2018. The FastPost service will no longer be available from this date. More>>

ALSO:

Property Institute: English Backs Of Debt To Income Plan

Property Institute of New Zealand Chief Executive Ashley Church is applauding today’s decision, by Prime Minister Bill English, to take Debt-to-income ratios off the table as a tool available to the Reserve Bank. More>>

ALSO:

Divesting: NZ Super Fund Shifts Passive Equities To Low-Carbon

The NZ$35 billion NZ Super Fund’s NZ$14 billion global passive equity portfolio, 40% of the overall Fund, is now low-carbon, the Guardians of New Zealand Superannuation announced today. More>>

ALSO:

Split Decision - Appeal Planned: EPA Allows Taranaki Bight Seabed Mine

The Decision-making Committee, appointed by the Board of the Environmental Protection Authority to decide a marine consent application by Trans-Tasman Resources Ltd, has granted consent, subject to conditions, for the company to mine iron sands off the South Taranaki Bight. More>>

ALSO: